Clinical Trial Update: Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating the PLK1 inhibitor Onvansertib in relapsed small cell lung cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Onvansertib (onvansertib)

Snippet

Sponsor: University of Maryland, Baltimore | Conditions: Small-cell Lung Cancer, Small Cell Lung Carcinoma | Phase 2 | Status: RECRUITING